Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

UNICANCER

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: Private

Established: 1964-01-01

Employees: 101

Market Cap: -

Website: http://www.unicancer.fr

Clinical Trials

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Phase 3

Recruiting

Conditions: Prostate Cancer Metastatic

Interventions: Drug: 177Lu-PMSA-617
Drug: Standard of Care

First Posted Date: 2024-07-11

Last Posted Date: 2024-12-20

Lead Sponsor: UNICANCER

Target Recruit Count: 500

Registration Number: NCT06496581

Locations: 🇫🇷
Institut de Cancérologie de l'Ouest, Saint-Herblain, France
🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
CHRU Brest, Brest, France

and more 20 locations

Dose individualization of chemotherapy in patients with gastrointestinal cancers lacking a specific liver enzyme

Phase 2

Recruiting

Conditions: Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication

Interventions: Drug: FOLFOX regimen
Drug: CAPOX regimen

First Posted Date: 2024-11-20

Last Posted Date: 2025-06-11

Lead Sponsor: Unicancer

Target Recruit Count: 400

Registration Number: 2023-509963-25-00

Locations: 🇫🇷
Grand Hopital De L Est Francilien, Meaux, France
🇫🇷
Hopital nord franche comté, Montbéliard, France
🇫🇷
Centre Hospitalier Universitaire D Orleans, Orleans Cedex 2, France

and more 35 locations

Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

Phase 2

Recruiting

Conditions: HER2-positive Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: Discontinuation of the anti-HER2 maintenance therapy
Device: Monitoring with signatera test

First Posted Date: 2024-06-10

Last Posted Date: 2025-02-20

Lead Sponsor: UNICANCER

Target Recruit Count: 170

Registration Number: NCT06450314

Locations: 🇫🇷
Centre Eugène marquis, Rennes, France

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Phase 2

Recruiting

Conditions: Ampulla of Vater Carcinoma
Duodenum Adenocarcinoma
Adrenocortical Carcinoma
Neuroendocrine Carcinoma
Small Bowel Adenocarcinoma
Gastric Adenocarcinoma
Pancreatic Adenocarcinoma
Soft Tissue Sarcoma

Interventions: Drug: Chemotherapy
Drug: Dostarlimab

First Posted Date: 2024-03-27

Last Posted Date: 2024-07-26

Lead Sponsor: UNICANCER

Target Recruit Count: 120

Registration Number: NCT06333314

Locations: 🇫🇷
Institut de Cancérologie de l'Ouest, Saint-Herblain, France
🇫🇷
Institut du Cancer Avignon-Provence, Avignon, France
🇫🇷
CHU Jean Minjoz, Besançon, France

and more 18 locations

Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging

Phase 3

Recruiting

Conditions: Prostatic Cancer, Castration-Resistant

Interventions: Drug: Darolutamide 300 mg
Drug: Androgen deprivation therapy
Radiation: Stereotactic body radiation therapy

First Posted Date: 2024-02-26

Last Posted Date: 2024-12-20

Lead Sponsor: UNICANCER

Target Recruit Count: 336

Registration Number: NCT06276465

Locations: 🇫🇷
Groupe Hospitalier Bretagne Sud, Lorient, France
🇫🇷
Centre Azuréen de Cancérologie, Mougins, France
🇫🇷
CHU de Saint-Etienne, Saint-Étienne, France

and more 1 locations

Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroesophageal cancer

Phase 2

Recruiting

Conditions: Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment

Interventions: Drug: Lonsurf
Drug: Oxaliplatin
Drug: Trastuzumab
Drug: Panitumumab
Drug: Bevacizumab
Drug: Nivolumab

First Posted Date: 2024-07-26

Last Posted Date: 2025-06-20

Lead Sponsor: Unicancer

Target Recruit Count: 73

Registration Number: 2023-508724-35-00

Locations: 🇫🇷
Centre Hospitalier Universitaire Amiens Picardie, Amiens Cedex 1, France
🇫🇷
Institut De Cancerologie De Lorraine, Vandouvre Les Nancy, France
🇫🇷
CH St Malo - Hôpital Broussais, Saint-Malo, France

and more 15 locations

Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-negative breast cancer (i.e. without hormone receptor or HER2 protein receptor)

Phase 2

Recruiting

Conditions: Triple negative breast cancer

Interventions: Drug: Pembrolizumab 25 mg/ml
Drug: Paclitaxel injection

First Posted Date: 2024-05-30

Last Posted Date: 2024-08-26

Lead Sponsor: Unicancer, Institut Gustave Roussy

Target Recruit Count: 364

Registration Number: 2023-504620-26-00

Locations: 🇫🇷
Centre Hospitalier Regional Universitaire De Tours, Tours, France
🇫🇷
Centr Georges Francois Leclerc, Dijon, France
🇫🇷
Centre Hospitalier Universitaire De Saint Etienne, St Etienne Cedex 2, France

and more 42 locations

Capecitabine plus pembrolizumab in patients with triple negative breast cancer after chemoimmunotherapy and surgery

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.

Interventions: Drug: Pembrolizumab injection
Drug: Capecitabine tablets
Radiation: Local radiotherapy

First Posted Date: 2024-11-14

Last Posted Date: 2024-11-14

Lead Sponsor: Unicancer

Target Recruit Count: 220

Registration Number: 2023-505291-30-01

Locations: 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷
Hospi Grand Ouest, St Nazaire, France
🇫🇷
Centre Hospitalier Departemental Vendee, La Roche Sur Yon Cedex 9, France

and more 21 locations

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

Phase 2

Recruiting

Conditions: Leptomeningeal Metastasis
Leptomeningeal Disease
HER2-positive Metastatic Breast Cancer

First Posted Date: 2023-04-05

Last Posted Date: 2024-02-06

Lead Sponsor: UNICANCER

Target Recruit Count: 30

Registration Number: NCT05800275

A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Not Applicable

Recruiting

Conditions: Metastatic Colorectal Cancer
BRAF V600E Mutation Positive

Interventions: Other: Collection of blood samples

First Posted Date: 2022-12-06

Last Posted Date: 2024-12-13

Lead Sponsor: UNICANCER

Target Recruit Count: 400

Registration Number: NCT05639413

Locations: 🇫🇷
CH Fleyriat, Bourg-en-Bresse, France
🇫🇷
CH Dr TECHER, Calais, France
🇫🇷
CH Louis Pasteur, Le Coudray, France

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy